SNTI Stock Overview
Operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Senti Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.17 |
| 52 Week High | US$7.43 |
| 52 Week Low | US$1.52 |
| Beta | 2.75 |
| 11 Month Change | -6.03% |
| 3 Month Change | -24.89% |
| 1 Year Change | -39.77% |
| 33 Year Change | -97.83% |
| 5 Year Change | n/a |
| Change since IPO | -97.83% |
Recent News & Updates
Recent updates
Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?
Dec 28
Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?
Sep 27Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platform
Sep 22Senti Biosciences GAAP EPS of -$0.86, revenue of $1.36M
Aug 16Is Senti Biosciences (NASDAQ:SNTI) In A Good Position To Invest In Growth?
Jun 13Shareholder Returns
| SNTI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.0% | 2.4% | 2.2% |
| 1Y | -39.8% | 16.2% | 31.7% |
Return vs Industry: SNTI underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: SNTI underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| SNTI volatility | |
|---|---|
| SNTI Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SNTI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SNTI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 48 | Tim Lu | www.sentibio.com |
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
Senti Biosciences, Inc. Fundamentals Summary
| SNTI fundamental statistics | |
|---|---|
| Market cap | US$9.71m |
| Earnings (TTM) | -US$70.87m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs SNTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNTI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$9.12m |
| Gross Profit | -US$9.12m |
| Other Expenses | US$61.75m |
| Earnings | -US$70.87m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -15.48 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SNTI perform over the long term?
See historical performance and comparison